Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U; EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Dimopoulos MA, et al. Among authors: facon t. Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3. Ann Oncol. 2021. PMID: 33549387 Free article. No abstract available.
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Moreau P, et al. Among authors: facon t. J Clin Oncol. 1997 Feb;15(2):660-6. doi: 10.1200/JCO.1997.15.2.660. J Clin Oncol. 1997. PMID: 9053491 Clinical Trial.
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Moreau P, et al. Among authors: facon t. Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731. Blood. 2002. PMID: 11806971 Free article. Clinical Trial.
Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C, Grosbois B, Beris P, Duguet C, Attal M, Harousseau JL, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Among authors: facon t. Hematol J. 2000;1(3):186-9. doi: 10.1038/sj.thj.6200031. Hematol J. 2000. PMID: 11920188 Clinical Trial.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. Among authors: facon t. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.
Stem-cell transplantation in multiple myeloma.
Harousseau JL, Moreau P, Attal M, Facon T, Avet-Loiseau H. Harousseau JL, et al. Among authors: facon t. Best Pract Res Clin Haematol. 2005;18(4):603-18. doi: 10.1016/j.beha.2005.01.005. Best Pract Res Clin Haematol. 2005. PMID: 16026740 Review.
415 results